News
![Novartis HQ](https://pharmaphorum.com/wp-content/uploads/2017/06/Novartis-HQ.jpg)
Blow for Novartis as ligelizumab can't top Xolair in phase 3
Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but with biosimilars looming the company has been looking